Bavarian Nordic A/S banner
B

Bavarian Nordic A/S
OTC:BVNRY

Watchlist Manager
Bavarian Nordic A/S
OTC:BVNRY
Watchlist
Price: 9.725 USD 3.73%
Market Cap: $2.3B

Relative Value

The Relative Value of one BVNRY stock under the Base Case scenario is hidden USD. Compared to the current market price of 9.725 USD, Bavarian Nordic A/S is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BVNRY Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

BVNRY Competitors Multiples
Bavarian Nordic A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Bavarian Nordic A/S
OTC:BVNRY
14.9B USD 2.4 10.9 4.6 6.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
362.5B USD 5.9 86.5 14.4 20
US
Amgen Inc
NASDAQ:AMGN
187.5B USD 5.1 24.5 14.2 14.2
US
Gilead Sciences Inc
NASDAQ:GILD
170.3B USD 5.8 20.1 12.5 15.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.3B USD 9.6 29.1 21.9 22.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.5B USD 5.5 17.4 12.8 14.6
AU
CSL Ltd
ASX:CSL
66.8B AUD 3.1 34.3 11.3 14.3
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.3B USD 11.2 132.1 73.9 82.1
P/E Multiple
Earnings Growth PEG
DK
B
Bavarian Nordic A/S
OTC:BVNRY
Average P/E: 44.4
10.9
-10%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
86.5
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.5
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.1
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.1
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
13%
1.3
AU
CSL Ltd
ASX:CSL
34.3
10%
3.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
132.1
84%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
B
Bavarian Nordic A/S
OTC:BVNRY
Average EV/EBITDA: 20.7
4.6
-12%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.4
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.8
18%
0.7
AU
CSL Ltd
ASX:CSL
11.3
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
73.9
67%
1.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
B
Bavarian Nordic A/S
OTC:BVNRY
Average EV/EBIT: 23.8
6.5
-15%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.2
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.5
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.6
23%
0.6
AU
CSL Ltd
ASX:CSL
14.3
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
82.1
69%
1.2
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett